华蟾素注射液联合CHOP方案治疗非霍奇金淋巴瘤临床研究

Clinical observation of huachansu injection combined with CHOP regimen in treatment of NHL

目的观察华蟾素联合CHOP方案治疗非霍奇金淋巴瘤的疗效及毒性。方法 48例非霍奇金淋巴瘤患者随机分为华蟾素联合CHOP方案组(A组)和CHOP方案组(B组),A组:24例患者接受环磷酰胺750mg.m2,静脉注射,第1d;阿霉素50mg.m2,静脉注射,第1d;长春新碱1.4mg.m2,静脉注射,第1d;强的松100mg.d2,口服,第1～5d;华蟾素20ml,加入5%葡萄糖250ml内静脉滴注,第1～14d。B组24名患者接受CHOP方案化疗同A组,不应用华蟾素,两组均为21d为1周期,化疗4个周期。结果 A组:CR10例(41.7%),PR12例(50.0%),SD1例(4.2%),PD1例(4.2%),有效率91.7%,疾病控制率为95.8%;B组:CR11例(45.8%),PR4例(16.7%),SD6例(25.0%),PD3例(12.5%),有效率62.5%,疾病控制率为87.5%。结论华蟾素联合CHOP方案治疗非霍奇金恶性淋巴瘤疗效较好,不良反应轻,患者可耐受。

Objective To observe the efficiency and toxicity of huachansu injection combined with CHOP regimen in the treatment of non-Hodgkin’S Lymphoma（NHL）.Method Totally 48 patients were randomized into huachansu injection plus CHOP regimen group（group A） and CHOP regimen group（group B）.group A： twenty-four patients were treated with bolus injertion of CTX 750mg/m^2,day1;bolus injertion of ADM 50mg/m^2,day1;bolus injertion of VCR 1.4mg/m^2,day1;PDN 100mg/d^2,day1-5;intravenous infusion of huachansu injection 20ml on day1-14.Group B： twenty-four patients were treated with CHOP regimen without huachansu injection.1 cycle was 21 days,treated 4 cycles.Results 10 of 24 assessable patients in group A achieved complete response（CR）;11 patient in group B.12 patients in group A had partial response（PR）;4 patients in group B.1 ones in group A had stable disease（SD）;6 ones in group B.1 patients in group A had progressive disease（PD）;3 ones in group B.The response rate in group A was 91.7%;62.5% in group B.Conclusions Huchansu injection combined with CHOP regimen was an effective regimen with tolerable toxicity in the treatment of advanced breast cancer.